All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

The prevalence of overweight/obese humans worldwide brings an enormous risk of metabolic and cardiovascular diseases as well as large healthcare costs. Fish oil is associated with a body weight/fat reduction effect in high fat diet-fed obese animal models \[[@pone.0142652.ref001]--[@pone.0142652.ref004]\]. The potential anti-obesity mechanisms involved in fish oil have been proposed in these studies, including increased adipocyte apoptosis \[[@pone.0142652.ref002]\], increased plasma adiponectin levels \[[@pone.0142652.ref003], [@pone.0142652.ref005]\], and altered fat oxidation and energy expenditure \[[@pone.0142652.ref004], [@pone.0142652.ref006]\]. However, it remains unknown whether fish oil consumption can combat obesity in humans though there is emerging evidence that it can improve lipid profile \[[@pone.0142652.ref007]--[@pone.0142652.ref009]\] and cardiovascular function \[[@pone.0142652.ref010]\] in many human trials. The results of previous randomized controlled trials on possible weight reduction effects of fish oil in overweight/obese human are controversial, partly because of the limited number of included subjects or varied intervention methods. Therefore, this meta-analysis aimed to systematically examine the possible anti-obesity effects of fish oil with/without combination of life modification intervention in overweight/obese adults.

Method and Search Strategy {#sec007}
==========================

This meta-analysis was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance \[[@pone.0142652.ref011]\]. We searched electronic databases in Embase, PubMed, web of knowledge, and the Cochrane Library for relevant records using the terms "fish-oil", "fish oil", "ducosahexaenoic acid", "DHA", "eicosapentaenoic acid", "EPA", and "n-3 polyunsaturated fatty acids". These terms were paired with the vocabulary "body composition", "obese", "overweight", "weight loss", "weight reduction", or "obesity". The search was limited to human randomized and placebo-controlled studies. Meanwhile, we manually searched reference lists of relevant review or original articles.

Study selection criteria {#sec008}
------------------------

Studies were included for analysis if they qualified the following criteria: 1) they were reported as a prospective, randomized (parallel or crossover), blind (double or single) and controlled trials, regardless of sample size; 2) they analyzed human subjects (≥18 y of age and body mass index (BMI) ≥25) who were assigned to either fish oil /marine diet or a control group for ≥4 weeks; 3) reported at least one of the following body composition parameters including body weight, BMI, waist circumference, and waist/hip ratio (WHR).

Data extraction and quality assessment {#sec009}
--------------------------------------

The literature search and data extraction were performed independently by two authors (S.D. and J.J.) according to standardized inclusion criteria with standardized individual results. Discrepancies were resolved by discussion with a third author (W.F.).The extracted data included the following parts: study design characteristics (crossover or parallel, double or single blind), participants characteristics (number, sex, age, and general health status), intervention strategies (dose of n-3 PUFA, ratio of EPA to DHA, treatment options in control groups, and combination with life modification intervention), study duration, reported changes in the body composition measurement (changes of body weight, BMI, waist circumstance, and WHR). For trials with more than one intervention group (with different doses of fish oil or with different intervention), multiple comparisons were considered. An assessment of study quality was performed independently by S.D. and J.J. according to the quality scores proposed by Jadad et al \[[@pone.0142652.ref012]\]. Some authors were contacted by email for original data if they were not available in the literatures.

Statistical analysis {#sec010}
--------------------

Analysis endpoints were calculated based upon the changes from baseline to post-treatment. Pooled effects were reported as standardized mean differences (SMDs) and 95% confidence intervals (CIs). The Cochrane\'s test was used to assess inter-study heterogeneity. Heterogeneity was identified as significant among the trials if the *P* value was \<0.10, or I^2^ \> 50% \[[@pone.0142652.ref013]\]. A random-effects model was used to estimate the pooled effects, which provided more generalized results. Furthermore, the predefined subgroup analyses were performed to explore the possible influence of study characteristics on study outcomes. Sensitivity analyses were also performed by omitting the studies with short follow-up duration. Egger regression asymmetry tests \[[@pone.0142652.ref014]\] and funnel plots were used to assess potential publication bias. *P* values were 2-tailed with statistical significance set at 0.05. Statistical analyses were performed with Stata software (version 12.0; Stata Corp).

Results {#sec011}
=======

Search results {#sec012}
--------------

In total, 456 articles were initially identified through the database search. Of these, 4 records were duplicated and 412 records were excluded because the objectives of these studies were irrelevant to the current meta-analysis, or because lacking randomization and control. Of the 40 potentially relevant records identified, 21 \[[@pone.0142652.ref009], [@pone.0142652.ref015]--[@pone.0142652.ref034]\] met the inclusion criteria for this meta-analysis. 19 were excluded because 3 were not randomized controlled trials \[[@pone.0142652.ref008], [@pone.0142652.ref035], [@pone.0142652.ref036]\], 1 compared fish diet with fish oil supplements \[[@pone.0142652.ref037]\], 1 compared the mixture of linoleic acid and n-3 PUFAs with placebo \[[@pone.0142652.ref038]\], 1 did not provide n-3 PUFAs dosage \[[@pone.0142652.ref039]\], 2 had a treatment duration of only 3 weeks \[[@pone.0142652.ref040], [@pone.0142652.ref041]\], 3 included infants or children \[[@pone.0142652.ref042]--[@pone.0142652.ref044]\], 7 did not provide related body compositions data \[[@pone.0142652.ref035], [@pone.0142652.ref045]--[@pone.0142652.ref050]\], and 1 did not report the number of both groups \[[@pone.0142652.ref051]\] ([Fig 1](#pone.0142652.g001){ref-type="fig"}).

![PRISMA 2009 flow diagram illustrates the study selection procedure.\
*From*: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *P*referred *R*eporting *I*tems for *S*ystematic Reviews and *M*eta-*A*nalyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097. **For more information, visit** [www.prisma-statement.org](http://www.prisma-statement.org).](pone.0142652.g001){#pone.0142652.g001}

Study characteristics {#sec013}
---------------------

Data extracted from 1652 individuals who participated in the 21 studies were analyzed in this meta-analysis ([Table 1](#pone.0142652.t001){ref-type="table"}). The studies investigated by Hill et al \[[@pone.0142652.ref018]\], Mori et al \[[@pone.0142652.ref026]\], and Munro et al \[[@pone.0142652.ref027]\] included two randomized comparisons in participants who underwent both fish oil alone and combined with a weight loss program. The studies investigated by Thorsdottir et al \[[@pone.0142652.ref030]\], Sjoberg et al \[[@pone.0142652.ref029]\], and Crochemore et al \[[@pone.0142652.ref021]\] included two randomized comparisons in participants who were treated with two different doses of n-3 PUFAs. Finally, 30 sets of data comparing fish oil treatment with controls were enrolled. All of the included comparisons were randomized controlled trials with 23 in a double-blind and 7 in a single-blind design. All of the studies included subjects of 18 years or older who were overweight or obese. Fish oil capsules were supplied orally in all of the studies except one, which fed marine food to the treatment group \[[@pone.0142652.ref030]\]. For the convenience of data pooling, the \"high dose fish oil\" group was selected as the \"treatment\" group while the \"low dose fish oil\" was selected as the control group for analysis in the study of Moore et al \[[@pone.0142652.ref009]\]. Overall, the median n3-PUFAs dose was 1.92 g/day (range: 0.54--11.3 g/day), and the ratio of EPA to DHA varied from 0.23 to 1.55. One study used highly purified EPA only \[[@pone.0142652.ref020]\]. Median treatment duration with n-3 PUFAs was 12 weeks (range: 4--24 weeks). For those with life modification intervention, subjects were given dietary caloric restriction in eleven studies, both caloric restriction and physical exercise in one study \[[@pone.0142652.ref016]\] or physical exercise only in one study \[[@pone.0142652.ref018]\].

10.1371/journal.pone.0142652.t001

###### Overview and characteristics of included studies.

![](pone.0142652.t001){#pone.0142652.t001g}

  Study                        Design         Subjects number   Age y   Male %   BMI   General health               Total dose g/d   EPA/DHA    Duration wk   Control number   Control oil               Dropout %   Body composition parameters reported   Life style modification   Quality score
  ---------------------------- -------------- ----------------- ------- -------- ----- ---------------------------- ---------------- ---------- ------------- ---------------- ------------------------- ----------- -------------------------------------- ------------------------- ---------------
  Mori et al, 1999a            Parallel       33                54      73       33    hypertension                 3.65             NR         16            16               NR                        NR          Wt BMI WC WHR                          no                        1
  Moore et al, 2006a           single blind   55                51      35       31    Healthy                      0.64             NR         24            24               low fish oil              6           Wt WC                                  no                        3
  Moore et al, 2006b           single blind   57                51      35       31    Healthy                      0.64             NR         24            30               low fish oil              6           Wt WC                                  no                        3
  Hill et al,2007a             Parallel       38                51      32       34    cardiovascular risk factor   1.92             0.23       6             20               sunflower oil             13          Wt BMI                                 no                        5
  Kabir et al, 2007            Parallel       26                55      0        30    T2DM                         1.8              1.5        8             14               paraffin oil              NR          Wt                                     no                        5
  Itoh et al, 2007             single blind   52                52      41       30    Healthy                      1.8              only EPA   12            26               saline                    NR          BMI WC                                 no                        1
  Cussons et al,2009           Crossover      25                33      0        35    PCOS                         3.32             0.48       8             25               olive oil                 0           BMI WHR                                no                        2
  Hartwich et al,2009          Parallel       41                55      34       35    metabolic syndrome           1.24             NR         12            22               sunflower oil             NR          BMI                                    no                        2
  Sjoberg et al,2010a          Parallel       33                53      54       32    Healthy                      0.64             0.23       12            17               sunola oil                17          BMI                                    no                        3
  Sjoberg et al,2010b          Parallel       34                53      54       32    Healthy                      1.28             0.23       12            17               sunola oil                17          BMI                                    no                        3
  Sjoberg et al,2010c          Parallel       34                53      54       32    Healthy                      1.92             0.23       12            17               sunola oil                17          BMI                                    no                        3
  Tierney et al,2011           single blind   206               55      44       32    Met S                        1.24             NR         12            106              sunflower oil             14          Wt BMI WC                              no                        3
  Vargas et al,2011            Parallel       34                30      0        34    PCOS                         3.5              1.48       6             17               soybean oil               18          Wt BMI WC                              no                        3
  Gammelmark et al, 2012       Parallel       50                57      48       30    Healthy                      1.12             1.33       6             24               olive oil                 2           BMI                                    no                        3
  Itariu et al,2012            Parallel       55                38      16       46    Severely obese               3.36             1.21       8             28               butterfat                 11          Wt BMI WHR                             no                        3
  Rafraf et al, 2012           Parallel       64                27      0        29    PCOS                         1.2              1.5        8             31               paraffin oil              5           Wt BMI WHR WC                          no                        5
  Crochemore et al,2012a       single blind   27                61      0        31    T2DM                         0.54             1.55       4             13               gelatin                   NR          BMI WC                                 no                        2
  Crochemore et al,2012b       single blind   27                61      0        31    T2DM                         0.9              1.55       4             13               gelatin                   NR          BMI WC                                 no                        2
  Munro et al, 2013a           Parallel       39                46      23       32    Healthy                      2.04             0.26       4             19               sunola oil                7           Wt BMI WHR WC                          no                        5
  Mori et al, 1999b            Parallel       30                54      60       33    hypertension                 3.65             NR         16            16               NR                        NR          Wt BMI WC WHR                          diet                      1
  Mendez-Sanchez et al, 2001   Parallel       35                38      0        34    Healthy                      11.3             NR         6             11               NR                        0           Wt BMI                                 diet                      3
  Krebs et al,2006             Parallel       93                45      0        35    hyperinsulinemia             4.2              0.45       24            26               linoleic and oleic acid   20          Wt BMI WC                              diet                      3
  Hill et al,2007b             Parallel       37                51      32       34    cardiovascular risk factor   1.92             0.23       12            18               sunflower oil             13          Wt BMI BF                              exercise                  5
  Thorsdottir et al, 2007a     Parallel       140               31      43       30    Healthy                      3                NR         8             66               sunflower oil             7           Wt BMI WHR WC                          diet                      3
  Thorsdottir et al, 2007b     Parallel       134               31      43       30    Healthy                      1.5              NR         8             66               sunflower oil             14          Wt BMI WHR WC                          diet                      3
  Kratz et al,2008             Parallel       26                38      39       30    Healthy                      2.88             NR         14            13               NR                        21          Wt BMI                                 diet                      2
  DeFina et al,2011            Parallel       128               46      31       33    Healthy                      3                5          24            64               soybean/corn oil          4           Wt BMI WC                              diet and exercise         5
  Munro et al, 2013b           Parallel       39                46      23       32    Healthy                      2.04             0.26       8             19               sunola oil                7           Wt BMI WHR WC                          diet                      5
  Munro et al,2013c            Parallel       35                40      NR       33    Healthy                      2.04             0.26       12            18               sunola oil                23          Wt BMI WHR WC                          diet                      5
  Wong et al, 2013             single blind   25                60      56       33    Healthy                      3.36             1.21       16            12               none                      7           Wt BMI WHR WC                          diet                      2

NR, not reported; PCOS, polycystic ovary syndrome; T2DM, type 2 diabetes; Met S, metabolic syndrome; Wt, body weight; BMI, body mass index; WHR, waist hip ratio; WC, waist circumference.

General health, overall health status apart from overweight/obese.

The study by Thorsdottir et al had a fish oil capsules group (1.5 g/d EPA + DHA) and fatty fish diet group (3g/d EPA+DHA).

The study by Crochemore et al was given fish oil capsules with 0.54 or 0.9 g/d EPA +DHA.

The study by Sjoberg et al was given fish oil capsules with 0.64, 1.28, or 1.92g/d EPA +DHA.

The study by Moore et al compared 4.5g/week EPA+DHA plus rapeseed oil with 0.7g/week EPA+DHA plus rapeseed oil; 4.5g/week EPA+DHA plus sunflower oil with 0.7g/week EPA+DHA plus sunflower oil.

The studies by Mori, Hill, and Munro et al included comparisons with participants underwent fish oil alone or combined with weight loss program.

Effects of fish oil on body weight changes {#sec014}
------------------------------------------

In total, 21 comparisons with 1329 subjects investigated the effect of fish oil on body weight changes. No significant heterogeneity (I^2^ = 25.2%, *P* = 0.14) was found. The calculated results indicated that fish oil was not associated with a body weight reduction (SMD = -0.07, 95% CI -0.21 to 0.07, *P* = 0.31; [Fig 2A](#pone.0142652.g002){ref-type="fig"}) compared with controls.

![Forest plots from meta-analyses for the effects of fish oil on changes in body weight (A), BMI (B), waist circumference (C), and WHR (D).](pone.0142652.g002){#pone.0142652.g002}

Comparisons were divided into two independent analyses to assess whether fish oil in combination with life modification altered the analysis results. Of the studies, 10 comparisons \[[@pone.0142652.ref009], [@pone.0142652.ref018], [@pone.0142652.ref019], [@pone.0142652.ref022], [@pone.0142652.ref026]--[@pone.0142652.ref028], [@pone.0142652.ref031], [@pone.0142652.ref032]\] with 607 subjects investigated the effects of fish oil on changes in body weight alone. No significant heterogeneity (I^2^ = 24.8%, *P* = 0.22) was found. The calculated results indicated that fish oil was not associated with reduced body weight (SMD = -0.004, 95% CI -0.20 to 0.19, *P* = 0.97). Further subgroup analyses according to predefined study characteristics (including mean age, male proportion, total dose and ratio of EPA to DHA, follow-up duration, study design, and quality score) were also not statistically significant, which indicated that the relationship of fish oil supplementation with body weight changes seemed to not be influenced by these factors ([Table 2](#pone.0142652.t002){ref-type="table"}).

10.1371/journal.pone.0142652.t002

###### Subgroup estimation of the effects of fish oil on body weight changes.

![](pone.0142652.t002){#pone.0142652.t002g}

  ----------------------------- ------------------------ ------------------------------- ---------------------- --------- ------------------------ --------------- ---------------------- ---------
  **Change in Body weight**                                                                                                                                                               
                                **Alone**                **Combined with weight loss**                                                                                                    
                                **Studies (subjects)**   **I** ^**2**^                   **WMD \[95%CI\]**      ***P***   **Studies (subjects)**   **I** ^**2**^   **WMD \[95%CI\]**      ***P***
  **Mean age (y)**                                                                                                                                                                        
  ≥50                           6(415)                   29%                             0.13\[-0.12,0.39\]     0.31      3(92)                    0%              -0.34\[-0.77,0.09\]    0.12
  \<50                          4(192)                   0%                              -0.17\[-0.45,0.12\]    0.25      8(630)                   41%             -0.09\[-0.31,0.14\]    0.46
  **Male (%)**                                                                                                                                                                            
  ≥30                           5(389)                   37%                             0.17\[-0.12,0.45\]     0.25      8(555)                   20%             -0.19\[-0.38,0.01\]    0.07
  \<30                          5(218)                   0%                              -0.17\[-0.44,0.10\]    0.21      3(167)                   25%             -0.13\[-0.32,0.06\]    0.79
  **BMI (kg/m** ^**2**^ **)**                                                                                                                                                             
  ≥32                           6(405)                   0%                              -0.01\[-0.21, 0.19\]   0.92      8(422)                   8%              -0.02\[-0.24,0.19\]    0.84
  \<32                          4(202)                   57%                             0.10\[-0.33,0.54\]     0.64      3(300)                   18%             -0.28\[-0.54,-0.02\]   0.04
  **Dose (g/d)**                                                                                                                                                                          
  ≥1.5                          6(225)                   0%                              -0.10\[-0.36,0.17\]    0.46      11(722)                  25%             -0.13\[-0.32,0.06\]    0.17
  \<1.5                         4(382)                   54%                             0.13\[-0.20,0.46\]     0.44      ---                      ---             ---                    ---
  **EPA/DHA**                                                                                                                                                                             
  ≥1                            4(179)                   0%                              -0.17\[-0.47,0.13\]    0.26      2(153)                   24%             0.07\[-0.36,0.49\]     0.25
  \<1                           2(77)                    0%                              -0.21\[-0.66,0.25\]    0.38      4(204)                   42%             -0.10\[-0.51,0.31\]    0.19
  NR                            4(351)                   39%                             0.23\[-0.07,0.54\]     0.13      5(365)                   0%              -0.28\[-0.49,-0.07\]   0.64
  **Duration (wk)**                                                                                                                                                                       
  ≥12                           4(351)                   39%                             0.23\[-0.07,0.54\]     0.13      7(374)                   17%             0.03\[-0.22,0.27\]     0.82
  \<12                          6(256)                   0%                              -0.18\[-0.43,0.07\]    0.15      4(348)                   0%              -0.32\[-0.54,-0.11\]   0.004
  **Study design**                                                                                                                                                                        
  DB                            7(289)                   0%                              -0.12\[-0.36,0.11\]    0.31      10(697)                  31%             -0.12\[-0.32,0.08\]    0.24
  SB                            3(318)                   57%                             0.23\[-0.16,0.62\]     0.24      1(25)                    ---             -0.32\[-1.11,0.47\]    0.43
  **Score**                                                                                                                                                                               
  ≥3                            9(574)                   41%                             -0.14\[-0.37,0.08\]    0.21      8(641)                   41%             -0.13\[-0.32,0.06\]    0.21
  \<3                           1(33)                    0%                              -0.07\[-0.50,0.37\]    0.77      3(81)                    0%              -0.07\[-0.50,0.37\]    0.77
  **Change in Body weight**                                                                                                                                                               
                                **Alone**                **Combined with weight loss**                                                                                                    
                                **Studies (subjects)**   **I** ^**2**^                   **WMD \[95%CI\]**      ***P***   **Studies (subjects)**   **I** ^**2**^   **WMD \[95%CI\]**      ***P***
  **Mean age (y)**                                                                                                                                                                        
  ≥50                           6(415)                   29%                             0.13\[-0.12,0.39\]     0.31      3(92)                    0%              -0.34\[-0.77,0.09\]    0.12
  \<50                          4(192)                   0%                              -0.17\[-0.45,0.12\]    0.25      8(630)                   41%             -0.09\[-0.31,0.14\]    0.46
  **Male (%)**                                                                                                                                                                            
  ≥30                           5(389)                   37%                             0.17\[-0.12,0.45\]     0.25      8(555)                   20%             -0.19\[-0.38,0.01\]    0.07
  \<30                          5(218)                   0%                              -0.17\[-0.44,0.10\]    0.21      3(167)                   25%             -0.13\[-0.32,0.06\]    0.79
  **BMI (kg/m** ^**2**^ **)**                                                                                                                                                             
  ≥32                           6(405)                   0%                              -0.01\[-0.21, 0.19\]   0.92      8(422)                   8%              -0.02\[-0.24,0.19\]    0.84
  \<32                          4(202)                   57%                             0.10\[-0.33,0.54\]     0.64      3(300)                   18%             -0.28\[-0.54,-0.02\]   0.04
  **Dose (g/d)**                                                                                                                                                                          
  ≥1.5                          6(225)                   0%                              -0.10\[-0.36,0.17\]    0.46      11(722)                  25%             -0.13\[-0.32,0.06\]    0.17
  \<1.5                         4(382)                   54%                             0.13\[-0.20,0.46\]     0.44      ---                      ---             ---                    ---
  **EPA/DHA**                                                                                                                                                                             
  ≥1                            4(179)                   0%                              -0.17\[-0.47,0.13\]    0.26      2(153)                   24%             0.07\[-0.36,0.49\]     0.25
  \<1                           2(77)                    0%                              -0.21\[-0.66,0.25\]    0.38      4(204)                   42%             -0.10\[-0.51,0.31\]    0.19
  NR                            4(351)                   39%                             0.23\[-0.07,0.54\]     0.13      5(365)                   0%              -0.28\[-0.49,-0.07\]   0.64
  **Duration (wk)**                                                                                                                                                                       
  ≥12                           4(351)                   39%                             0.23\[-0.07,0.54\]     0.13      7(374)                   17%             0.03\[-0.22,0.27\]     0.82
  \<12                          6(256)                   0%                              -0.18\[-0.43,0.07\]    0.15      4(348)                   0%              -0.32\[-0.54,-0.11\]   0.004
  **Study design**                                                                                                                                                                        
  DB                            7(289)                   0%                              -0.12\[-0.36,0.11\]    0.31      10(697)                  31%             -0.12\[-0.32,0.08\]    0.24
  SB                            3(318)                   57%                             0.23\[-0.16,0.62\]     0.24      1(25)                    ---             -0.32\[-1.11,0.47\]    0.43
  **Score**                                                                                                                                                                               
  ≥3                            9(574)                   41%                             -0.14\[-0.37,0.08\]    0.21      8(641)                   41%             -0.13\[-0.32,0.06\]    0.21
  \<3                           1(33)                    0%                              -0.07\[-0.50,0.37\]    0.77      3(81)                    0%              -0.07\[-0.50,0.37\]    0.77
  ----------------------------- ------------------------ ------------------------------- ---------------------- --------- ------------------------ --------------- ---------------------- ---------

Of the studies, 11 comparisons \[[@pone.0142652.ref016], [@pone.0142652.ref018], [@pone.0142652.ref023], [@pone.0142652.ref024], [@pone.0142652.ref026], [@pone.0142652.ref027], [@pone.0142652.ref030], [@pone.0142652.ref033], [@pone.0142652.ref052]\] with 722 subjects investigated the effects of fish oil on body weight changes combined with diet restriction and/or exercise. No significant heterogeneity (I^2^ = 24.7%, *P* = 0.21) was found among them. The calculated results indicated that fish oil had no additional weight loss effects (SMD = -0.13, 95% CI 0.32 to 0.06, *P* = 0.17). Subgroup analyses according to treatment duration demonstrated that studies with treatment less than 12 weeks favored significant weight loss effects of fish oil (*P* = 0.004). Sensitivity analysis excluded study with only 6 weeks of treatment \[[@pone.0142652.ref025]\], but they still suggested an insignificant relationship with fish oil and change in body weight (*P* = 0.22). Other predefined study characteristics were also not statistically significant ([Table 2](#pone.0142652.t002){ref-type="table"}). Only one study included in this meta-analysis examined the combined effects of fish oil and regular exercise on body composition \[[@pone.0142652.ref018]\]. Sensitivity analysis excluding this trial did not seem to change the results (*P* = 0.28).

Effects of fish oil on BMI changes {#sec015}
----------------------------------

Of the studies, 27 comparisons with 1514 subjects investigated the effects of fish oil on BMI changes. No significant heterogeneity (I^2^ = 25.9%, *P* = 0.11) was found. The calculated results indicated that fish oil was not associated with a significant reduction in BMI (SMD = -0.09, 95% CI -0.22 to 0.03, *P* = 0.14; [Fig 2B](#pone.0142652.g002){ref-type="fig"}).

Among the studies, 16 comparisons \[[@pone.0142652.ref009], [@pone.0142652.ref015], [@pone.0142652.ref017]--[@pone.0142652.ref021], [@pone.0142652.ref026]--[@pone.0142652.ref028], [@pone.0142652.ref031]--[@pone.0142652.ref033]\] with 792 subjects investigated the effects of fish oil on changes in body weight alone. No significant heterogeneity (I^2^ = 0.0%, *P* = 0.66) was found. The calculated results indicated that fish oil had no effect in reducing BMI (SMD = -0.03, 95% CI -0.17 to 0.11, *P* = 0.64).

Of the studies, 11 comparisons \[[@pone.0142652.ref016], [@pone.0142652.ref018], [@pone.0142652.ref023]--[@pone.0142652.ref027], [@pone.0142652.ref029], [@pone.0142652.ref030], [@pone.0142652.ref052]\] with 722 subjects investigated the effect of fish oil on changes in BMI in combination with weight loss programs. The calculated results indicated that fish oil had no additional effect in reducing BMI (SMD = -0.17, 95% CI -0.42 to 0.07, *P* = 0.17) when combined with weight loss programs. In view of considerable heterogeneity (I^2^ = 53.8%, *P* = 0.02), subgroup analyses were performed to explore the potential difference between study characteristics and the effect of fish oil on changes in BMI. The results of subgroup analyses suggested that those with distinctive anti-obesity effects were studies with duration less than 12 week (*P* = 0.001), which could largely explain the considerable heterogeneity. After excluding the study with only 6 weeks of treatment \[[@pone.0142652.ref025]\], sensitivity analyses decreased heterogeneity (I^2^ = 46.3%, *P* = 0.06); however, the non-significant anti-obesity results remained (*P* = 0.32). Other factors including mean age, sex proportion, and total fish oil dose seemed irrelevant with the possible effects of fish oil on change in BMI combined with a weight loss program ([Table 3](#pone.0142652.t003){ref-type="table"}). Furthermore, excluding the study that investigated the additional anti-obesity effect of fish oil combined with physical exercise \[[@pone.0142652.ref018]\] did not seem to change the results (*P* = 0.28).

10.1371/journal.pone.0142652.t003

###### Subgroup estimation of the effects of fish oil on BMI changes.

![](pone.0142652.t003){#pone.0142652.t003g}

  ----------------------------- ------------------------ ------------------------------- ---------------------- --------- ------------------------ --------------- ---------------------- ---------
  **Change in BMI**                                                                                                                                                                       
                                **Alone**                **Combined with weight loss**                                                                                                    
                                **Studies (subjects)**   **I** ^**2**^                   **WMD \[95%CI\]**      ***P***   **Studies (subjects)**   **I** ^**2**^   **WMD \[95%CI\]**      ***P***
  **Mean age (y)**                                                                                                                                                                        
  ≥50                           11(575)                  0%                              0.053\[-0.11,0.22\]    0.52      3(92)                    0%              -0.35\[-0.78,0.08\]    0.12
  \<50                          5(217)                   0%                              -0.18 \[-0.43,0.08\]   0.18      8(630)                   65%             -0.13\[-0.43,0.17\]    0.39
  **Male (%)**                                                                                                                                                                            
  ≥30                           9(521)                   0%                              0.08\[-0.10,0.25\]     0.38      8(555)                   45%             -0.17\[-0.42,0.08\]    0.19
  \<30                          7(271)                   0%                              -0.18\[-0.41,0.05\]    0.13      3(167)                   77%             -0.17\[-0.42,0.07\]    0.49
  **BMI (kg/m** ^**2**^ **)**                                                                                                                                                             
  ≥32                           11(572)                  0%                              0.02\[-0.14,0.18\]     0.80      8(422)                   54%             -0.16\[-0.48,0.16\]    0.34
  \<32                          5(220)                   0%                              -0.11\[-0.38,0.16\]    0.42      3(300)                   41%             -0.26\[-0.58,0.06\]    0.11
  **Dose (g/d)**                                                                                                                                                                          
  ≥1.5                          8(310)                   0%                              -0.05\[-0.27,0.16\]    0.64      11(722)                  54%             -0.17\[-0.42,0.07\]    0.17
  \<1.5                         8(482)                   0%                              0.01\[-0.17,0.19\]     0.89      ---                      ---             ---                    ---
  **EPA/DHA**                                                                                                                                                                             
  ≥1                            7(309)                   0%                              -0.15\[-0.38,0.07\]    0.18      2(153)                   26%             0.16\[-0.27,0.60\]     0.25
  \<1                           6(203)                   0%                              -0.15\[-0.41,0.11\]    0.26      4(204)                   45%             -0.13\[-0.55,0.29\]    0.14
  NR                            3(280)                   31%                             0.26\[-0.08,0.60\]     0.13      5(365)                   39%             -0.33\[-0.64,-0.04\]   0.16
  **Duration (wk)**                                                                                                                                                                       
  ≥12                           7(433)                   0%                              0.11\[-0.08,0.30\]     0.25      7(374)                   29%             0.05\[-0.22,0.32\]     0.73
  \<12                          9(359)                   0%                              -0.16\[-0.36,0.04\]    0.12      4(348)                   0%              -0.40\[-0.62,-0.18\]   0.00
  **Study design**                                                                                                                                                                        
  DB                            12(480)                  0%                              -0.05\[-0.23,0.13\]    0.69      10(697)                  58%             -0.17\[-0.43,0.09\]    0.20
  SB                            4(312)                   0%                              0.04\[-0.18,0.27\]     0.83      1(25)                    ---             -0.22\[-1.01,0.57\]    0.59
  **Score**                                                                                                                                                                               
  ≥3                            10(587)                  0%                              -0.06\[-0.22,0.11\]    0.97      8(641)                   65%             -0.22\[-0.51,0.08\]    0.15
  \<3                           6(205)                   14%                             0.10\[-0.19,0.38\]     0.32      3(81)                    0%              -0.03\[-0.47,0.41\]    0.89
  **Change in BMI**                                                                                                                                                                       
                                **Alone**                **Combined with weight loss**                                                                                                    
                                **Studies (subjects)**   **I** ^**2**^                   **WMD \[95%CI\]**      ***P***   **Studies (subjects)**   **I** ^**2**^   **WMD \[95%CI\]**      ***P***
  **Mean age (y)**                                                                                                                                                                        
  ≥50                           11(575)                  0%                              0.053\[-0.11,0.22\]    0.52      3(92)                    0%              -0.35\[-0.78,0.08\]    0.12
  \<50                          5(217)                   0%                              -0.18 \[-0.43,0.08\]   0.18      8(630)                   65%             -0.13\[-0.43,0.17\]    0.39
  **Male (%)**                                                                                                                                                                            
  ≥30                           9(521)                   0%                              0.08\[-0.10,0.25\]     0.38      8(555)                   45%             -0.17\[-0.42,0.08\]    0.19
  \<30                          7(271)                   0%                              -0.18\[-0.41,0.05\]    0.13      3(167)                   77%             -0.17\[-0.42,0.07\]    0.49
  **BMI (kg/m** ^**2**^ **)**                                                                                                                                                             
  ≥32                           11(572)                  0%                              0.02\[-0.14,0.18\]     0.80      8(422)                   54%             -0.16\[-0.48,0.16\]    0.34
  \<32                          5(220)                   0%                              -0.11\[-0.38,0.16\]    0.42      3(300)                   41%             -0.26\[-0.58,0.06\]    0.11
  **Dose (g/d)**                                                                                                                                                                          
  ≥1.5                          8(310)                   0%                              -0.05\[-0.27,0.16\]    0.64      11(722)                  54%             -0.17\[-0.42,0.07\]    0.17
  \<1.5                         8(482)                   0%                              0.01\[-0.17,0.19\]     0.89      ---                      ---             ---                    ---
  **EPA/DHA**                                                                                                                                                                             
  ≥1                            7(309)                   0%                              -0.15\[-0.38,0.07\]    0.18      2(153)                   26%             0.16\[-0.27,0.60\]     0.25
  \<1                           6(203)                   0%                              -0.15\[-0.41,0.11\]    0.26      4(204)                   45%             -0.13\[-0.55,0.29\]    0.14
  NR                            3(280)                   31%                             0.26\[-0.08,0.60\]     0.13      5(365)                   39%             -0.33\[-0.64,-0.04\]   0.16
  **Duration (wk)**                                                                                                                                                                       
  ≥12                           7(433)                   0%                              0.11\[-0.08,0.30\]     0.25      7(374)                   29%             0.05\[-0.22,0.32\]     0.73
  \<12                          9(359)                   0%                              -0.16\[-0.36,0.04\]    0.12      4(348)                   0%              -0.40\[-0.62,-0.18\]   0.00
  **Study design**                                                                                                                                                                        
  DB                            12(480)                  0%                              -0.05\[-0.23,0.13\]    0.69      10(697)                  58%             -0.17\[-0.43,0.09\]    0.20
  SB                            4(312)                   0%                              0.04\[-0.18,0.27\]     0.83      1(25)                    ---             -0.22\[-1.01,0.57\]    0.59
  **Score**                                                                                                                                                                               
  ≥3                            10(587)                  0%                              -0.06\[-0.22,0.11\]    0.97      8(641)                   65%             -0.22\[-0.51,0.08\]    0.15
  \<3                           6(205)                   14%                             0.10\[-0.19,0.38\]     0.32      3(81)                    0%              -0.03\[-0.47,0.41\]    0.89
  ----------------------------- ------------------------ ------------------------------- ---------------------- --------- ------------------------ --------------- ---------------------- ---------

Effects of fish oil on waist circumference changes {#sec016}
--------------------------------------------------

In total, 19 comparisons with 1273 subjects investigated the effects of fish oil on changes in waist circumference. No significant heterogeneity (I^2^ = 33.3%, *P* = 0.08) among the patients was observed. The calculated results indicated that fish oil could significantly reduce waist circumference (SMD = -0.16, 95% CI -0.31 to -0.02, *P* = 0.03; [Fig 2C](#pone.0142652.g002){ref-type="fig"}).

Of the comparisons, 11 \[[@pone.0142652.ref009], [@pone.0142652.ref019]--[@pone.0142652.ref021], [@pone.0142652.ref026]--[@pone.0142652.ref028], [@pone.0142652.ref031], [@pone.0142652.ref032]\] with 649 subjects investigated the effects of fish oil on change in waist circumference alone. No significant heterogeneity (I^2^ = 43.2%, *P* = 0.06) was observed. The calculated results indicated that fish oil did not have a significant effect to reduce waist circumference alone (SMD = -0.14 95% CI -0.36 to 0.09, *P* = 0.22).

However, 8 comparisons \[[@pone.0142652.ref016], [@pone.0142652.ref024], [@pone.0142652.ref026], [@pone.0142652.ref027], [@pone.0142652.ref052]\] with 624 subjects investigated the effects of fish oil on change in body waist circumference combined with a weight loss program. The results determined that fish oil had a significant additional effect in reducing waist circumference (SMD = -0.23 95% CI -0.40 to -0.06, *P* = 0.008; I^2^ = 6.8%, *P* = 0.38) in combination with a weight loss program.

Effects of fish oil on changes in waist hip ratio {#sec017}
-------------------------------------------------

Of the comparisons, 11 with 619 subjects investigated the effects of fish oil on changes in WHR. The calculated results suggested that fish oil could significantly reduce WHR (SMD = -0.52, 95% CI -0.76 to -0.27, *P* \<0.0005; [Fig 2D](#pone.0142652.g002){ref-type="fig"}).

In total, 5 comparisons \[[@pone.0142652.ref015], [@pone.0142652.ref019], [@pone.0142652.ref026]--[@pone.0142652.ref028], [@pone.0142652.ref052]\] with 216 subjects investigated the effects of fish oil on change in WHR alone. The calculated results indicated that fish oil had a significant effect in reducing WHR alone (SMD = -0.39 95% CI -0.72 to -0.07, *P* = 0.02) without significant heterogeneity (I^2^ = 37.3%, *P* = 0.17).

Among the studies, 6 comparisons \[[@pone.0142652.ref026], [@pone.0142652.ref027], [@pone.0142652.ref030], [@pone.0142652.ref052]\] with 403 subjects investigated the effects of fish oil on changes in WHR combined with a weight loss program. The results also indicated that fish oil had a significant effect in reducing WHR when combined with a weight loss program (SMD = -0.63 95% CI -1.00 to -0.25, *P* = 0.001). However, there was significant heterogeneity (I^2^ = 63.7%, *P* = 0.02) among these studies. Subgroup analyses were not available for these outcomes because of the limited number of the studies included.

Publication bias {#sec018}
----------------

No significant publication biases were observed through funnel plots ([Fig 3A and 3B](#pone.0142652.g003){ref-type="fig"}) and Egger's regression asymmetry tests for the effects of fish oil on changes in body weight (Egger's test *P* = 0.79) or BMI (Egger's test *P* = 0.18).

![Funnel plots from meta-analyses for the effects of fish oil on changes in body weight (A) and BMI (B).](pone.0142652.g003){#pone.0142652.g003}

Discussion {#sec019}
==========

In the current meta-analysis, we investigated the association between changes in body composition and fish oil supplementation in 21 randomized, placebo controlled trials involving overweight or obese adults. Interestingly, in contrast to the results found in obese animal models, we did not detect a remarkable anti-obesity benefit of fish oil in overweight/obese subjects. However, fish oil might assist with improving waist hip ratio (WHR). We performed subgroup analyses to investigate the potential influences of study characteristics on pooled BMI and body weight outcomes. The results favoring significant weight reduction effects in the fish oil group combined with a weight loss program were those with treatment duration of less than 12 weeks. Furthermore, sensitivity analysis excluded the study that was only 6 weeks in duration, which demonstrated more stable negative results of fish oil supplementation compared with placebo. Gender differences have been considered as a potential factor to influence the effect of fish oil on reducing weight \[[@pone.0142652.ref027], [@pone.0142652.ref030], [@pone.0142652.ref040], [@pone.0142652.ref053]\]; however, in the subgroup analysis, we did not detect a significant difference with fish oil and weight reduction in different male proportions.

Munro et al \[[@pone.0142652.ref052]\] explained that perhaps n-3 PUFAs were more effective in preventing weight gain rather than assisting in weight loss. In humans, several studies have reported a significantly higher concentration of n-3 PUFAs in normal weight individuals compared with obese individuals \[[@pone.0142652.ref054], [@pone.0142652.ref055]\]. In addition, Couet C et al \[[@pone.0142652.ref056]\] observed that body fat mass was decreased and basal fat oxidation was significantly increased in 6 healthy volunteers with fish oil supplementation. However, Jakobsen et al \[[@pone.0142652.ref057]\] investigated 1998 lean adults and did not observe that the proportion of plasma n-3 PUFA was associated with a subsequent 1-year change in body weight. Large scale (both lean and obese subjects) and long term trials were needed to draw definite results.

Our results were supported by some previous observational studies. Garaulet et al \[[@pone.0142652.ref058], [@pone.0142652.ref059]\] investigated the n-3 PUFAs content of perivisceral and omental adipose tissue samples in 84 obese patients. Their study determined that n-3 PUFAs (in particular the DHA) were inversely related to abdominal obesity and adipocyte size. Matsumura et al \[[@pone.0142652.ref060]\] evaluated visceral fat by abdominal computed tomography in 91 subjects who had been fed with EPA 1800 mg/day and 74 control during a 6-month period. Their study observed that visceral fat area of male subjects in the EPA group trended to decrease (*P* = 0.06) during the 6 months of treatment. A number of pre-clinical and clinical studies \[[@pone.0142652.ref061]--[@pone.0142652.ref063]\] demonstrated an ameliorative effect of supplemental fish oil in reducing hepatic lipid content in non-alcoholic fatty liver disease (NAFLD). There were 2 review articles \[[@pone.0142652.ref064], [@pone.0142652.ref065]\] suggesting n3-PUFAs as potential treatments for liver inflammation associated with fat accumulation.

Because of the current limited information, we could not completely explain why fish oil decreased abdominal fat. However, increased n-3 PUFAs induced lipogenic gene down-regulation in adipose tissues. Second, it might have been related to changes in lipid synthesis and/or storage as a result of the profound reduction in postprandial lipemia associated with n-3 PUFAs \[[@pone.0142652.ref066]\]. Deck et al \[[@pone.0142652.ref067]\] reported that modest doses of fish oil supplementation caused a significant reduction in triglyceride levels by a mean of 2.21mmol/L and increased the high-density lipoprotein cholesterol by a mean of 0.13mmol/L. This was the first comprehensive meta-analysis to examine the effects of fish oil on changes of body composition in overweight and obese adults. We included only randomized controlled trials, which had a low probability of bias and other confounding factors of the original studies. Multiple electronic databases had been searched to minimize database bias. Selected trails had been carefully checked to minimize multiple publication bias. Individual search and extraction were conducted to minimize the bias in the provision of data and inclusion criteria.

Previous systematic reviews \[[@pone.0142652.ref068], [@pone.0142652.ref069]\] concluded that n-3 PUFAs might have potential benefits improving body composition in humans. However, their enrollment ranges (including lean and overweight/obese adults) were larger, and their study duration (3--12 weeks) less than ours. Furthermore, they did not use the meta-analysis method, which allow for greater statistical power than individual trials.

However, the results of this meta-analysis should be interpreted with caution because of several limitations. First, potential sources of heterogeneity included participant variations as well as intervention intensity and duration. The included trials had many differences including subject health status, concurrent therapy, fish oil supplement doses and compositions, follow-up durations, and treatment methods. These differences might have substantially contributed to the research heterogeneity. However, we expounded the influence of these factors through subgroup analyses. Second, treatment durations of the included study were relatively short (4 to 24 weeks), which made subgroup analysis according to study duration not compelling. Notably, plasma DHA levels increased significantly from 12 to 24 weeks \[[@pone.0142652.ref050]\]; however, in our meta-analysis, short- and long-term studies were assigned equal importance. We have limited information from RCTs on the relationship of body weight and fish oil in the longer term. Only 3 studies \[[@pone.0142652.ref009], [@pone.0142652.ref016], [@pone.0142652.ref024]\] included in this meta-analysis had treatment duration of 24 weeks. Tapsell et al \[[@pone.0142652.ref070]\] investigated the anti-obesity effects of fish diet for 12 month. However, the participants were in a "free living" state with self-reported food intake, and the dropout rate was as high as 47%. Some authors \[[@pone.0142652.ref027]\] suggested that it might be easier to manage dietary compliance when working with laboratory animals compared with humans. This might be an important reason underlying why the anti-obesity effects of fish oil supplementation were not as obvious in humans as animals.

In conclusion, from the results of our meta-analysis, we cannot obtain effective proof that fish oil intakes may decrease body weight in overweight/obese adults. However, it may help reduce the waist hip ratio especially when combined with life modification interventions. Because of the limited follow-up duration, the results should be treated with caution. Further large-scale research over a long time is needed to determine definitive conclusions.
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